Jeffrey R. Strich, MD, M.H.S.
Lasker Clinical Research Scholar
Laboratory of Critical Illness Pathogenesis and Therapeutics
NHLBI
Research Topics
Dr. Strich’s research interests are focused on developing therapies for and understanding the role of the innate immune system in infections that cause critical illness through human clinical trials, large animal models and ex vivo translational studies with a particular focus on bacterial sepsis and SARS-CoV-2 infection. Dr. Strich is particularly interested in studying the contribution and therapeutics targeting low-density neutrophils (LDNs), a subset of neutrophils traditionally identified in the peripheral blood mononuclear cell (PBMC) fraction of gradient density separation.
Biography
Dr. Strich received his undergraduate degree from the University of Connecticut in Molecular and Cell Biology, his degree in Medicine from the Uniformed Services University of the Health Sciences, and his Masters in Health Services in Clinical Research from the Duke University School of Medicine. He completed residency training in Internal Medicine at Georgetown University Hospital and then completed a combined fellowship in Critical Care Medicine and Infectious Diseases at the National Institutes of Health.
Dr. Strich is a Medical Officer in the United States Public Health Services Commissioned Corps. Prior to pursuing his degree in Medicine he served as a Special Assistant in the Office of the Surgeon General. Dr. Strich is a member of the Infectious Disease Society of America (IDSA) the Society of Critical Care Medicine, and serves on the editorial board of Critical Care Explorations. He holds an appointment as an Adjunct Assistant Professor of Medicine at the Uniformed Services University of the Health Sciences.
Selected Publications
- Strich JR, Ramos-Benitez MJ, Warner S, Kendall H, Stein S, Platt AP, Ramelli SC, Curran SJ, Lach I, Allen K, Babyak A, Perez-Valencia LJ, Minai M, Sun J, Vannella KM, Alves D, Herbert R, Chertow DS. Klebsiella pneumoniae induces dose-dependent shock, organ dysfunction, and coagulopathy in a nonhuman primate critical care model. mBio. 2024:e0194324.
- Warner S, Teague HL, Ramos-Benitez MJ, Panicker S, Allen K, Gairhe S, Moyer T, Parachalil Gopalan B, Douagi I, Shet A, Kanthi Y, Suffredini AF, Chertow DS, Strich JR. R406 reduces lipopolysaccharide-induced neutrophil activation. Cell Immunol. 2024;403-404:104860.
- Wigerblad G, Warner SA, Ramos-Benitez MJ, Kardava L, Tian X, Miao R, Reger R, Chakraborty M, Wong S, Kanthi Y, Suffredini AF, Dell'Orso S, Brooks S, King C, Shlobin O, Nathan SD, Cohen J, Moir S, Childs RW, Kaplan MJ, Chertow DS, Strich JR. Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. Sci Adv. 2023;9(1):eade8272.
- Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, Cohen J, Ahmad K, Brown AW, Khangoora V, Aryal S, Migdady Y, Kyte JJ, Joo J, Hays R, Collins AC, Battle E, Valdez J, Rivero J, Kim IH, Erb-Alvarez J, Shalhoub R, Chakraborty M, Wong S, Colton B, Ramos-Benitez MJ, Warner S, Chertow DS, Olivier KN, Aue G, Davey RT, Suffredini AF, Childs RW, Nathan SD. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Clin Infect Dis. 2022;75(1):e491-e498.
- Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, Suffredini AF, Childs RW, Chertow DS. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. J Infect Dis. 2021;223(6):981-984.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
View additional Principal Investigators in Microbiology and Infectious Diseases
This page was last updated on Tuesday, January 14, 2025